4. What is that status of each of your mAb programs? For example, have you nominated any lead
candidates, are you awaiting patient samples, etc.?

5. Do you have any metrics on lead candidates available yet, such as neutralization titers? If so,
what are they?

All the best,
Karen

Karen Tkach Tuzman, Ph.D.

Head, Discovery & Preclinical Development
Associate Editor, BioCentury Inc.
650-595-5333 x 144 (office)

www.biocentury.com

Notice: This communication (including any attachments) constitutes an electronic communication within
the meaning of the Electronic Communications Privacy Act, 18 USC 2510, and its disclosure is strictly
limited to the recipient(s) intended by the sender of this message. This communication (including any
attachments) contains proprietary information, is protected under U.S. and foreign copyright and other
intellectual property law, and may contain confidential material for the sole use of the intended
recipient. Any unauthorized review, use, disclosure, dissemination, copying or distribution of this
communication (including any attachments), or any of their respective contents, is strictly prohibited. If
you are not the intended recipient, please contact the sender by return email and destroy all copies of
the original message.

NIH-001738
